Bicara Therapeutics (BCAX) just picked up a double dose of index recognition, joining both the NASDAQ Biotechnology Index and the S&P Biotechnology Select Industry Index. This shift can quietly reshape demand dynamics for its shares. See our latest analysis for Bicara Therapeutics. The latest index inclusions come after a powerful 90 day share price return of 64.02 percent from a current share price of 17.55 dollars, even though the 1 year total shareholder return is still negative. This...